Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
New antibody drugs using PPMX's proprietary antibody technology
Applicable field (uses covered by this announcement)
Development of new treatments for specific disease areas
Contract Date29 October 2026
Relationship between the counterparty and the company
Perseus Proteomics Inc.4882
Relationship with the Company
The joint research partner with which the joint research agreement was signed. Capital and personnel relationships: Not disclosed
CounterpartyKYORIN Pharmaceutical Co.,Ltd.
Head office: Chiyoda-ku, Tokyo; Representative Director, President and CEO: Ogiwara Yutaka (荻原 豊). Other details: Not disclosed
Impact on Business Performance
The agreement is expected to have a minor impact on results for the current fiscal year.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | New antibody drugs using PPMX's proprietary antibody technology |
| Counterparty | KYORIN Pharmaceutical Co.,Ltd. |
| Counterparty overview | Head office: Chiyoda-ku, Tokyo; Representative Director, President and CEO: Ogiwara Yutaka (荻原 豊). Other details: Not disclosed |
| Relationship with the Company | The joint research partner with which the joint research agreement was signed. Capital and personnel relationships: Not disclosed |
| Contract Date | 29 October 2026 |
| Applicable area | Development of new treatments for specific disease areas |
| Impact on Business Performance | The agreement is expected to have a minor impact on results for the current fiscal year. |
Items this document does not state (11)
Contract ValueOffering priceLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historySource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To develop new treatments for specific disease areas and create new antibody drugs.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.